Bioverativ Inc (NASDAQ:BIVV) has received an average rating of “Hold” from the seventeen analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $60.54.
A number of brokerages have weighed in on BIVV. Zacks Investment Research upgraded shares of Bioverativ from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Morgan Stanley restated an “underweight” rating and issued a $47.00 price objective (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a report on Monday, October 23rd. Royal Bank of Canada began coverage on shares of Bioverativ in a report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price objective on the stock. Finally, Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Wednesday, September 20th.
Shares of Bioverativ (NASDAQ:BIVV) opened at $53.93 on Friday. Bioverativ has a fifty-two week low of $40.00 and a fifty-two week high of $64.41.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. equities analysts anticipate that Bioverativ will post 2.45 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of Bioverativ during the third quarter valued at approximately $137,000. TCI Wealth Advisors Inc. purchased a new stake in shares of Bioverativ during the third quarter valued at approximately $186,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Bioverativ during the third quarter valued at approximately $190,000. Canada Pension Plan Investment Board bought a new position in Bioverativ during the third quarter valued at approximately $194,000. Finally, ACG Wealth bought a new position in Bioverativ during the third quarter valued at approximately $205,000. Hedge funds and other institutional investors own 95.99% of the company’s stock.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.